Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
Type:
Application
Filed:
April 17, 2013
Publication date:
January 16, 2014
Applicant:
BioNTech AG
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.
Type:
Grant
Filed:
February 18, 2016
Date of Patent:
March 6, 2018
Assignee:
BioNTech AG
Inventors:
Özlem Türeci, Ugur Sahin, Gerd Helftenbein, Volker Schlüter